Stay updated on Pembrolizumab for Rare Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Rare Tumors Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Version updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.
    Difference
    0.1%
    Check dated 2025-09-14T19:14:26.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.1%
    Check dated 2025-09-07T15:36:37.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The web page has been updated to include new resources and clinical trial information related to various cancers, while several previous cancer-related terms and resources have been removed.
    Difference
    7%
    Check dated 2025-08-31T11:55:09.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    There are no significant changes to the web page content.
    Difference
    0.2%
    Check dated 2025-08-24T07:55:45.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.
    Difference
    0.6%
    Check dated 2025-08-17T04:23:38.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-10T00:23:56.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Rare Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.